Deferasirox (ICL670) Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 470

Clinical Trials

Deferasirox has been evaluated in numerous clinical trials investigating its efficacy in systemic metal accumulation and hematologic disorders, including chronic transfusional iron overload, myelodysplastic syndromes, beta-thalassemia, Diamond-Blackfan anemia, and aplastic anemia. Spanning Early Phase 1 through Phase 4, these studies comprise completed, actively recruiting, terminated, and not yet recruiting protocols. Research is sponsored by pharmaceutical corporations such as Novartis and Elpen Pharmaceutical Co., alongside prominent academic centers including the Fred Hutchinson Cancer Center and the University of Pisa.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06784336	RECRUITING	Allogeneic Stem Cell Transplant	University of Michigan Rogel Cancer Center	2025-10-15	PHASE2
NCT06964971	NOT_YET_RECRUITING	Transfusion-dependent Non-severe Aplastic Anemia	The First Affiliated Hospital of Zhejiang Chinese Medical University	2025-05-20
NCT07023666	RECRUITING	Sickle Cell Disease	Inova Health Care Services	2025-10-07	PHASE2
NCT03387475	COMPLETED	Myelodysplasia	University Hospital, Grenoble	2018-02-20	PHASE2
NCT06468423	COMPLETED	Pateints of β-thalassemia Major With Iron Overload	RESnTEC, Institute of Research	2023-01-01
NCT03203850	TERMINATED	Hereditary Hemochromatosis	Novartis Pharmaceuticals	2018-01-11	PHASE2
NCT05392101	COMPLETED	Sickle Cell Disease	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	2021-07-20	PHASE2
NCT03637556	COMPLETED	Thalassemia Major	DisperSol Technologies, LLC	2019-08-20	PHASE2
NCT03920657	TERMINATED	Myelodysplastic Syndromes	Fondazione Italiana Sindromi Mielodisplastiche-ETS	2019-10-04	PHASE2
NCT04423237	Recruiting	Iron Overload	University of Pisa\|IRCCS Burlo Garofolo\|University of Genova	2020-09-30	--
NCT02993224	COMPLETED	Transfusion-dependent Thalassemia; Non-transfusion-dependent Thalassemia	Novartis Pharmaceuticals	2017-07-27	PHASE2
NCT03372083	COMPLETED	Iron Overload	Novartis Pharmaceuticals	2018-01-16	PHASE4
NCT03920657	Terminated	Myelodysplastic Syndromes	Fondazione Italiana Sindromi Mielodisplastiche-ETS	2019-10-04	Phase 2
NCT02720536	COMPLETED	Chronic Iron Overload	Novartis Pharmaceuticals	2016-08-16	PHASE3
NCT02854722	UNKNOWN	Postmenopausal Osteoporosis	Second Affiliated Hospital of Soochow University	2018-01-15	PHASE2
NCT01718366	UNKNOWN	MDS	Groupe Francophone des Myelodysplasies	2013-02	PHASE1; PHASE2
NCT02943668	TERMINATED	Anemia; Myelodysplastic Syndrome	Fred Hutchinson Cancer Center	2017-03-02	PHASE2
NCT02069886	WITHDRAWN	Thalassemia (Transfusion Delendent)	Novartis Pharmaceuticals	2014-12	PHASE4
NCT02435212	COMPLETED	Transfusion-dependent Anemia	Novartis Pharmaceuticals	2015-10-21	PHASE2
NCT00940602	COMPLETED	Myelodysplastic Syndromes	Novartis Pharmaceuticals	2010-03-22	PHASE2
NCT03372083	Completed	Iron Overload	Novartis Pharmaceuticals\|Novartis	2018-01-16	Phase 4
NCT02233504	COMPLETED	High Risk MDS or AML Patients	Abramson Cancer Center at Penn Medicine	2014-08	EARLY_PHASE1
NCT01825512	COMPLETED	Chronic Iron Overload	Consorzio per Valutazioni Biologiche e Farmacologiche	2014-03-17	PHASE3
NCT02474420	UNKNOWN	Beta-Thalassemia; Iron Overload	Kevin H.M. Kuo, MD, MSc, FRCPC	2015-06
NCT02761395	UNKNOWN	AL-Hijama in Thalassmia Major	Tanta University	2015-11
NCT01868477	COMPLETED	Low and Int 1-risk Myelodysplastic Syndrome	Novartis Pharmaceuticals	2014-01-28	PHASE2
NCT01892644	WITHDRAWN	Hemochromatosis; Myelodysplastic Syndromes	Haukeland University Hospital	2013-05	PHASE2
NCT02341495	TERMINATED	Acute Myeloid Leukemia	Elizabeth Henry	2013-02	PHASE2
NCT02038816	TERMINATED	Myelodysplastic Syndromes	Sunnybrook Health Sciences Centre	2014-03	PHASE2
NCT02413021	UNKNOWN	Acute Myeloid Leukemia; Acute Lymphoid Leukemia	Isfahan University of Medical Sciences	2016-05	PHASE1
NCT02663752	TERMINATED	Myelodysplastic Syndrome	Novartis Pharmaceuticals	2016-05-30	PHASE2
NCT02663752	Terminated	Myelodysplastic Syndrome	Novartis Pharmaceuticals\|Novartis	2016-05-30	Phase 2
NCT02125877	COMPLETED	Chronic Iron Overload Due to Transfusion-dependant Anemias	Novartis Pharmaceuticals	2014-07-08	PHASE2
NCT01948817	WITHDRAWN	Focus on Transfusion Dependent Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD	Novartis Pharmaceuticals	2014-02	PHASE2
NCT01927913	WITHDRAWN	Transfusional Iron Overload; Iron Overload; Iron Chelation; Beta-thalassemia; Transfusional Hemosiderosis; Iron Metabolism Disorders; Metabolic Diseases	Shire	2014-11-20	PHASE2
NCT01610297	COMPLETED	Iron Overload After Hematopoietic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major	Novartis Pharmaceuticals	2013-09	PHASE4
NCT01709032	COMPLETED	Thalassemia Major With Severe Transfusional Iron Overload	Children's Hospital of Philadelphia	2012-09	PHASE1; PHASE2
NCT02159040	TERMINATED	High Risk MDS	Novartis Pharmaceuticals	2014-09-11	PHASE2
NCT01709838	COMPLETED	Non-transfusion Dependent Thalassemia	Novartis Pharmaceuticals	2012-12-06	PHASE4
NCT01459718	TERMINATED	Transfusion-dependent β-thalassemia Patients; Cardiac Iron Overload	Novartis Pharmaceuticals	2011-01	PHASE2
NCT01724138	WITHDRAWN	β-thalassemia Major	Novartis Pharmaceuticals	2013-06	PHASE4
NCT01254227	COMPLETED	Cardiac Iron Overload	Novartis Pharmaceuticals	2011-01	PHASE2
NCT00600938	COMPLETED	Transfusional Iron Overload; Transfusional Hemosiderosis	Novartis Pharmaceuticals	2007-11	PHASE2
NCT01511848	UNKNOWN	Beta-thalassemia Major; Sickle Cell Disease; Iron Hemosiderosis	Ain Shams University	2012-02	PHASE2; PHASE3
NCT01058369	TERMINATED	Myelodysplastic Syndromes	University of Erlangen-Nürnberg Medical School	2010-04	PHASE2
NCT01284946	UNKNOWN	Porphyria Cutanea Tarda	Assistance Publique - Hôpitaux de Paris	2011-01	PHASE2
NCT00901199	COMPLETED	Thalassemia; Iron Overload	Elliott Vichinsky	2007-09	PHASE2
NCT01326845	TERMINATED	Myelodysplastic Syndrome; Transfusional Iron Overload	Novartis Pharmaceuticals	2011-12	PHASE4
NCT00560820	COMPLETED	β-thalassemia; Transfusional Iron Overload	Novartis Pharmaceuticals	2007-09	PHASE1
NCT01278056	COMPLETED	Non-alcoholic Steatohepatitis; Increased Iron Storage / Disturbed Distribution	Crolll Gmbh	2010-03	PHASE1; PHASE2
NCT01273766	COMPLETED	Acute Undifferentiated Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Langerhans Cell Histiocytosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Mast Cell Leukemia; Myelodysplastic Syndrome With Isolated Del(5q); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Myeloid/NK-cell Acute Leukemia; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Anemia; Refractory Multiple Myeloma; Secondary Acute Myeloid Leukemia; Secondary Myelofibrosis; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Waldenstrom Macroglobulinemia	Wake Forest University Health Sciences	2011-01	PHASE2
NCT00654589	COMPLETED	Iron Overload	Novartis Pharmaceuticals	2008-02	PHASE4
NCT00673608	COMPLETED	Hemoglobinopathies; Myelodysplastic Syndromes; Other Inherited or Acquired Anaemia; MPD Syndrome; Diamond-Blackfan Anemia; Other Rare Anaemias; Transfusional Iron Overload	Novartis	2007-11	PHASE4
NCT01159067	TERMINATED	Iron Overload; Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Atypical Chronic Myeloid Leukemia, BCR-ABL Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; de Novo Myelodysplastic Syndromes; Disseminated Neuroblastoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Poor Prognosis Metastatic Gestational Trophoblastic Tumor; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Neuroblastoma; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Splenic Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage II Ovarian Epithelial Cancer; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Malignant Testicular Germ Cell Tumor; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Ovarian Epithelial Cancer; Stage III Small Lymphocytic Lymphoma; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Breast Cancer; Stage IV Chronic Lymphocytic Leukemia; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Ovarian Epithelial Cancer; Stage IV Small Lymphocytic Lymphoma	City of Hope Medical Center	2010-07	PHASE2
NCT01250951	COMPLETED	Myelodysplastic Syndrome; Thalassemia	Novartis Pharmaceuticals	2009-12	PHASE4
NCT00564941	COMPLETED	Myelodysplastic Syndromes; Beta-Thalassemia	Novartis Pharmaceuticals	2007-12	PHASE4
NCT00873041	COMPLETED	Non-transfusion Dependent Thalassemia	Novartis Pharmaceuticals	2008-11	PHASE2
NCT00879242	COMPLETED	Beta Thalassemia Transfusion Dependent	Novartis Pharmaceuticals	2009-02	PHASE2
NCT01335035	COMPLETED	Iron Overload	Novartis Pharmaceuticals	2008-12	PHASE4
NCT00631163	COMPLETED	Chronic Anemia; Transfusional Hemosiderosis	Novartis Pharmaceuticals	2007-10	PHASE2
NCT00481143	COMPLETED	Myelodysplastic Syndromes; Transfusion Dependent Iron Overload	Novartis Pharmaceuticals	2007-05	PHASE4
NCT00981370	TERMINATED	Anemia, Sickle Cell; Transfusion Hemosiderosis	Children's Hospital Los Angeles	2009-04	PHASE3
NCT00845871	COMPLETED	Transfusional Hemosiderosis	Novartis Pharmaceuticals	2009-05	PHASE4
NCT00432627	COMPLETED	Hepatic Impairment	Novartis Pharmaceuticals	2006-12	PHASE1
NCT01349699	COMPLETED	Systemic Inflammatory Process; Anemia	Radboud University Medical Center	2010-02
NCT00599326	COMPLETED	Porphyria Cutanea Tarda	University of Texas Southwestern Medical Center	2008-01	PHASE3
NCT00469560	COMPLETED	Myelodysplastic Syndromes; Hemosiderosis	Gruppo Italiano Malattie EMatologiche dell'Adulto	2007-06	PHASE3
NCT00419770	COMPLETED	Mucormycosis	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	2007-10	PHASE2
NCT00447694	COMPLETED	Beta-thalassemia; Iron Overload	Novartis	2006-02	PHASE2
NCT00602446	TERMINATED	Breast Cancer; Iron Overload; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Neuroblastoma; Ovarian Cancer	Masonic Cancer Center, University of Minnesota	2007-08	PHASE2
NCT00738413	UNKNOWN	Thalassemia	Weill Medical College of Cornell University	2008-08	PHASE1; PHASE2
NCT00171821	COMPLETED	Transfusion-dependent Iron Overload	Novartis Pharmaceuticals	2005-04	PHASE3
NCT00749515	COMPLETED	Transfusion-dependent Hemachromatosis; Thalassemia Major; Sickle Cell Disease	Boston Children's Hospital	2008-03	PHASE4
NCT00235391	COMPLETED	Thalassemia; Sickle Cell Disease; Diamond Blackfan Anemia; Myelofibrosis	Novartis Pharmaceuticals	2005-10	PHASE3
NCT00303329	COMPLETED	Anemia; Hemosiderosis	Novartis Pharmaceuticals	2004-03	PHASE2
NCT02198508	COMPLETED	Beta-thalassemia Major	China Medical University Hospital	2007-07
NCT00171301	COMPLETED	Beta-thalassemia Major; Hemosiderosis; Iron Overload; Rare Anemia	Novartis Pharmaceuticals	2005-06	PHASE4
NCT00171210	COMPLETED	Transfusional Iron Overload in β-thalassemia	Novartis Pharmaceuticals	2004-10	PHASE3
NCT00110617	COMPLETED	Sickle Cell Disease; Iron Overload; Hemolytic Anemia	Novartis Pharmaceuticals	2005-05	PHASE2
NCT00110266	COMPLETED	Myelodysplastic Syndrome; Iron Overload	Novartis Pharmaceuticals	2005-07-25	PHASE2
NCT00390858	COMPLETED	Transfusional Iron Overload; β-thalassemia Major; Pediatric Rare Anemia	Novartis Pharmaceuticals	2003-09	PHASE2
NCT01033747	COMPLETED	Liver Iron Overload	Novartis Pharmaceuticals	2003-02	PHASE2; PHASE3
NCT00117507	COMPLETED	Myelodysplastic Syndromes; Iron Overload	Novartis Pharmaceuticals	2005-09	PHASE4
NCT00395629	COMPLETED	Iron Overload; Hereditary Hemochromatosis	Novartis Pharmaceuticals	2006-08	PHASE1; PHASE2
NCT00171171	COMPLETED	Beta-Thalassemia; Hemosiderosis	Novartis	2004-05	PHASE3
NCT00061763	COMPLETED	Beta-thalassemia; Myelodysplastic Syndromes; Fanconi Syndrome; Anemia, Diamond-Blackfan; Anemia, Aplastic	Novartis Pharmaceuticals	2003-05	PHASE2
NCT00379483	COMPLETED	Transfusional Iron Overload	Novartis Pharmaceuticals	2002-07	PHASE2
NCT00419172	COMPLETED	Healthy	Novartis	2007-01	PHASE1
NCT00427505	COMPLETED	Healthy	Novartis	2006-07	PHASE1

(data from https://clinicaltrials.gov, updated on 2026-07-21)

Check the Deferasirox (ICL670) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Deferasirox selectively binds ferric iron to form a stable complex, inducing cellular iron depletion that downregulates anti-apoptotic Bcl-xL expression and causes apoptotic cell death. By eliminating excess toxic iron, this mechanism mitigates tissue iron toxicity and provides therapeutic benefit in clinical conditions such as transfusional iron overload, beta-thalassemia, and myelodysplastic syndromes.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).